[Research Progress on Separating Graft Versus Host Disease and Graft Versus Tumor Effect--Review]

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only method for curing many hematopoietic benign or malignant diseases, from which a number of patients obtain long-term survival. However, graft versus host disease (GVHD) deeply hinders the development and clinical use of HSCT. Up to now, immune response triggered by donor's T cell has been considered to be the pathogenesis of GVHD. On the other side, donor's T cell has indispensable effect in competing with the tumor cells and reducing the disease recurrence rate. So, how to prevent GVHD, meanwhile, to retain graft versus tumor (GVT) effect, has become one of the challenging problems after HSCT. Recently, drugs such as trametinib and echinomycin, expanding regulatory T cells in vitro and advanced techniques such as conformal nanoencapsulation have shown optimistic results in experiments of separating GVHD and GVT effect, which are hopefully to be utilized in clinic in the future.